It’s too early to say which company — or companies — will win the coronavirus vaccine race. But we do have tools to identify the most promising players. It’s important to look at timelines, clinical trial data, and a company’s ability to fund and manufacture billions of doses of a safe and effective vaccine. More of this information is available now than was the case a few months ago.
Considering these elements, Moderna (NASDAQ:MRNA) and Pfizer (NYSE:PFE) would be on my buy list. The clinical-stage biotech and big pharma player are among the 11 programs currently in phase 3 trials. Both are working on messenger RNA (mRNA) vaccines. Unlike traditional vaccines, they don’t introduce weakened virus into the body. Instead, they instruct the body to make specific disease antigens to fight future infection. Let’s take a closer look at both companies to see exactly what makes them the best coronavirus